Side Effects of Bacillus Calmette-Guérin (BCG) in the Treatment of Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Bladder: Results of the EORTC Genito-Urinary Cancers Group Randomised Phase 3 Study Comparing One-third Dose with Full Dose and 1 Year with 3 Years of Maintenance BCG

Published 2013 View Full Article

Authors

Keywords

Journal

EUROPEAN UROLOGY

Volume 65, Issue 1, Pages 69-76

Publisher

Elsevier BV

Online

2013-07-25

DOI

10.1016/j.eururo.2013.07.021

Ask authors/readers for more resources

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

EUROPEAN UROLOGY

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Create your own webinar

Become a Peeref-certified reviewer